DSIP for Health & Longevity

Evidence Review created on 08/05/2026 using AI4L / Opus 5

Also known as: Delta Sleep-Inducing Peptide, Emideltide, Deltaran, DSIP-NH2

Motivation

DSIP (delta sleep-inducing peptide) is a short chain of nine amino acids that was first pulled out of the blood of sleeping rabbits in the 1970s and named for the deep, slow brain waves it appeared to bring on. It is not a sedative and not an approved medicine anywhere; it is made to order and sold mainly through compounding pharmacies and online peptide vendors.

Interest has never fully settled. Early human work in people with long-standing insomnia produced encouraging results that later studies struggled to repeat, and researchers have never found the gene, the precursor protein, or the docking site in the body that a true sleep hormone would be expected to have. A separate line of animal work, mostly Russian, has pointed instead toward effects on stress tolerance, cell damage, and lifespan, which is why the peptide keeps resurfacing in longevity circles.

This review examines what the human and animal evidence actually shows about DSIP, how it is used in practice, what is known and unknown about its safety, and where the regulatory picture stands.

Benefits - Risks - Protocol - Conclusion

Grokipedia

Delta-sleep-inducing peptide

A dedicated encyclopedic entry covering the peptide’s amino acid sequence, its 1977 isolation, and the contradictory record on slow-wave sleep induction across species. It is useful as a neutral factual baseline before reading the partisan clinical and commercial literature.

Examine

No Examine article exists for DSIP.

Examine covers dietary supplements and nutrients rather than unapproved injectable peptides. DSIP is not a dietary supplement in any jurisdiction and is obtainable only through compounding pharmacies or research-chemical suppliers, which places it outside the site’s editorial scope in the same way prescription medications are.

ConsumerLab

No ConsumerLab article exists for DSIP.

ConsumerLab performs independent purity and label-accuracy testing on retail dietary supplements. DSIP is not sold as a retail supplement and, like prescription medications and other injectable peptides, falls outside the products the organization tests; its published peptide coverage is limited to a general answer on BPC-157 and TB-500.

Systematic Reviews

No systematic reviews or meta-analyses for DSIP were found on PubMed as of August 5, 2026.

Mechanism of Action

DSIP is the nonapeptide Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu, molecular weight 849 daltons. Its defining feature is a negative one: after fifty years, no gene, no precursor protein, and no binding site have been identified for it, which is why any account of how it works remains provisional (Kovalzon & Strekalova, 2006).

Cortical slow-wave and spindle activity. Infusion into the brain’s ventricles produced spindle and delta activity on the EEG (electroencephalogram, a recording of the brain’s electrical activity) in rabbits, rats, and mice, with a more pronounced effect on REM (rapid eye movement) sleep reported in cats (Graf & Kastin, 1984); a later feline study found the opposite, with deep slow-wave sleep increased and REM sleep unchanged (Susić et al., 1987). The dose-response relationship is U-shaped rather than linear, meaning higher doses can produce less effect than moderate ones.
Excitatory-inhibitory balance. DSIP blocked the excitatory response of rat brain neurons to glutamate, the brain’s principal stimulating messenger (Umriukhin, 2002), and DSIP together with DSIP-12, a nonapeptide analogue carrying beta-alanine at position 2, reduced the severity of chemically provoked seizures (Stanojlović et al., 2005). This dampening of excitation, rather than direct activation of a sedative pathway, is the most consistently reproduced central effect.
Opioid-linked signalling. Early work found that DSIP’s slow-wave effect, like that of morphine and alcohol, was reversed by naloxone, an opioid-blocking drug, which motivated its use in withdrawal syndromes (Dick et al., 1984). The picture is not uniform: DSIP’s effect on pain threshold in rats was explicitly not naloxone-sensitive (Yehuda & Carasso, 1987), so the peptide is unlikely to be a simple opioid agonist.
Pineal and circadian modulation. DSIP modulates pineal N-acetyltransferase, the rate-limiting enzyme that converts serotonin toward melatonin, acting through the alpha-1 adrenergic receptor rather than binding the enzyme itself (Graf & Schoenenberger, 1987), and stimulates melatonin and serotonin release from isolated rat pineal glands (Ouichou et al., 1992).
Stress-hormone axis — competing findings. In rats, DSIP reduced corticosterone release driven by CRF (corticotropin-releasing factor, the brain signal that starts the stress-hormone cascade) (Graf et al., 1985). In healthy men, intravenous DSIP had no effect at all on ACTH (adrenocorticotropic hormone, the pituitary signal that tells the adrenal glands to release cortisol) or cortisol, whether stimulated by corticotropin-releasing hormone or by a meal (Späth-Schwalbe et al., 1995). The species gap here is unresolved and is a central weakness in the stress-protection argument.
Growth-hormone axis — species-discordant. DSIP stimulated growth hormone release in rats through combined hypothalamic and pituitary actions (Iyer & McCann, 1987), a finding still used to market the peptide as a recovery aid. The direct human test contradicts it: administration to healthy women did not influence growth hormone or prolactin secretion (Giusti et al., 1993). This is the same rodent-to-human discontinuity seen in the stress-hormone data, and it is the reason growth-hormone release is not listed among the expected benefits below.
Antioxidant and mitochondrial effects. DSIP raises the activity of superoxide dismutase, catalase, and the glutathione enzymes — the cell’s own antioxidant machinery — and suppresses lipid peroxidation, the chain-reaction damage that oxygen radicals inflict on cell membranes (Shustanova et al., 2001; Bondarenko et al., 2011). In isolated rat brain mitochondria it increased the rate of phosphorylating respiration and the respiratory control ratio, and pretreatment fully prevented the loss of mitochondrial respiratory capacity caused by low oxygen (Khvatova et al., 2003). A conflict of interest attaches to this entire line of work and to the Russian stress-adaptation literature cited below: the Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, which synthesized the peptide and developed and supplied the Deltaran preparation, provided co-authors on nearly all of these papers and has a direct interest in the compound’s adoption.
Competing overall explanations. Three interpretations coexist. The original view holds that DSIP is a genuine endogenous sleep factor. The sceptical view, argued in detail by Kovalzon, holds that DSIP itself is inactive on slow-wave sleep — certain synthetic analogues promote it while the natural sequence does not — and that a structurally similar but distinct peptide accounts for the immunoreactivity (the signal picked up by antibody-based DSIP assays, which cannot distinguish closely related sequences) and the biological effects attributed to DSIP. The third, dominant in the Russian literature, treats DSIP not as a hypnotic at all but as a general stress-adaptive modulator whose sleep effect is incidental (Koplik et al., 2008). None has been decisively excluded.

Key pharmacological properties. Half-life: very short, with proteolytic cleavage of the terminal tryptophan proceeding with a half-time of roughly 15 minutes in tissue preparations and disappearance from blood within minutes; phosphorylated and substituted analogues persist substantially longer (Graf et al., 1987). Selectivity: undefined, because no receptor has been identified; the peptide’s effects are inferred pharmacologically rather than from binding data. Tissue distribution: DSIP-like immunoreactivity is found in hypothalamic neurosecretory nuclei, throughout the brain, in peripheral organs, in plasma, and in human milk (Graf et al., 1984); a portion of peripherally injected peptide crosses the blood-brain barrier intact (Kastin et al., 1981) and it also passes the blood-cerebrospinal fluid barrier (Zlokovic et al., 1988). Metabolism: enzymatic hydrolysis by aminopeptidases and endopeptidases in plasma and brain tissue (Nakamura et al., 1993); there is no cytochrome P450 involvement, so the liver enzyme interactions that dominate small-molecule pharmacology (for example CYP3A4, the enzyme that clears roughly half of all prescription drugs) do not apply.

Historical Context & Evolution

Original purpose. DSIP was not developed as a therapy. In 1974 the Schoenenberger-Monnier group in Basel electrically stimulated the thalamus of rabbits to induce delta sleep, collected cerebral venous blood, dialysed it, and isolated the fraction that transferred delta sleep to recipient animals; the nonapeptide sequence was published in 1977. The object was to prove the century-old hypothesis that a circulating humoral factor drives sleep (Schoenenberger, 1984).
Move to human therapy. Once synthetic peptide was available, the Basel group tested it directly in people. A 1981 report in The Lancet described improved sleep in insomniacs (Schneider-Helmert et al., 1981), followed by a report on disturbed human sleep in Experientia (Schneider-Helmert & Schoenenberger, 1981). A 1984 special issue of European Neurology extended the work to withdrawal syndromes and chronic pain.
What the historical findings actually showed. The 1987 seven-night placebo-controlled study reported that night sleep improved with the first dose and further with repeated doses, that the effect persisted into the first post-treatment placebo night, and that sleep efficiency and daytime rest reached the levels of healthy controls, with significant gains in alertness and performance (Schneider-Helmert, 1987). The contemporaneous crossover study by Monti’s group found the same directional changes — fewer awakenings, shorter latency to non-REM sleep, less waking after sleep onset — but concluded they were not significant against baseline and were of little clinical significance (Monti et al., 1987). The 1992 Amsterdam double-blind study found higher sleep efficiency and shorter sleep latency with DSIP than placebo, but judged the effects weak and partly attributable to drift in the placebo group (Bes et al., 1992). The record is therefore genuinely split, not uniformly negative.
Why enthusiasm receded. Three things changed. Molecular biology matured, and the failure to clone a DSIP gene or identify a receptor became more damaging as those tools became routine. Larger and better-controlled sleep studies of other agents raised the comparison standard. And Kovalzon’s group reported that synthetic analogues promoted slow-wave sleep in rabbits and rats while DSIP itself did not, which suggested the assays that founded the field may have been detecting a different molecule (Kovalzon & Strekalova, 2006). Set against this, the peptide’s non-sleep effects — anticonvulsant, antioxidant, stress-protective — continued to replicate, so the retreat was specific to the sleep claim rather than general.
The parallel Russian programme. Work never stopped in the former Soviet Union. The Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry developed Deltaran, a DSIP-containing preparation, and the Petrov Institute of Oncology in St. Petersburg ran lifespan and carcinogenesis studies in mice through the 2000s (Popovich et al., 2003). This body of work reframed the peptide as a geroprotector — an agent intended to slow aging — rather than a hypnotic, and is the direct origin of its current standing in longevity practice. The relevant caveat is that the institute that synthesized the peptide supplied the authors on nearly every one of these papers.
The current phase. DSIP re-entered circulation through the online peptide market in the 2010s and acquired the assigned generic name emideltide. United States regulators placed it in the compounding category reserved for substances with significant safety risks in 2023, removed it from that category in April 2026, and put it before the Pharmacy Compounding Advisory Committee in July 2026, which declined to recommend it by 6 votes to 7 with 1 abstention (Snow et al., 2026). The matter is not settled: the agency has stated that the proposed rule, not the committee vote, will resolve it.

Expected Benefits

High 🟩 🟩 🟩

No benefit of DSIP currently reaches this evidence level. The entire controlled human record consists of a small number of studies in fewer than 60 participants in total, and no systematic review or meta-analysis exists.

Medium 🟩 🟩

Reduced Sleep-Onset Latency and Improved Sleep Efficiency in Disturbed Sleep ⚠️ Conflicted

DSIP shortens the time taken to fall asleep and raises the proportion of time in bed actually spent asleep in people whose sleep is already disturbed; healthy sleepers show only minor changes. The proposed mechanism is enhancement of spindle and delta activity together with dampening of glutamate-driven cortical excitation, rather than sedation. The evidence base is four small double-blind or placebo-controlled trials conducted between 1981 and 1992, of which two reported clinically meaningful improvement and two reported changes their own authors judged too weak to matter. The discrepancy tracks study design: the positive studies used repeated dosing across consecutive nights in severe chronic insomniacs, while the negative studies used shorter exposures and were more conservative about baseline drift. No trial since 1992 has attempted replication.

Magnitude: Across four controlled trials of 7 to 16 participants each, dosed at 25 nmol/kg intravenously, two reported that sleep efficiency reached healthy-control levels with carry-over into the following untreated night, while two found changes that did not separate convincingly from baseline.

Improved Next-Day Alertness and Psychomotor Performance

Beyond the night itself, DSIP has been reported to improve daytime functioning in people with chronic insomnia — alertness, mood, and performance on cognitive testing. The proposed mechanism is indirect, following from better sleep continuity, though a direct cortical effect has not been excluded. The evidence basis is one seven-night placebo-controlled study with extensive daytime testing, one open series in which mood and daytime performance improved alongside normalized sleep for follow-up periods of three to seven months (Kaeser, 1984), and a controlled report that intranasal DSIP increased the P300 brain-wave response, an electrical signal that indexes attention and information processing (Hruz et al., 2001). All three are small, and the open series is uncontrolled.

Magnitude: Not quantified in available studies.

Low 🟩

Symptom Relief During Alcohol and Opiate Withdrawal

Intravenous DSIP has been reported to abolish or markedly reduce the physical signs of withdrawal from alcohol and opiates within a short time, with anxiety improving more slowly than the somatic symptoms. The proposed mechanism is the naloxone-reversible opioid-linked signalling identified in the original animal work. The evidence basis is a single uncontrolled inpatient series and a later clinical letter (Soyka & Rothenhaeusler, 1997); there is no placebo comparison, no blinding, and no replication in four decades, so the result cannot be separated from the natural time course of detoxification or from concomitant care.

Magnitude: In a series of 107 inpatients, symptoms disappeared or improved markedly in 97% of those withdrawing from opiates and 87% of those withdrawing from alcohol; opiate withdrawal required more injections and had a longer course than alcohol withdrawal.

Reduction in Chronic Pain Intensity

DSIP has been reported to lower pain in people with treatment-resistant pain syndromes, with a parallel reduction in depressive symptoms. The proposed mechanism combines a central pain-blocking effect demonstrated after direct brain administration in animals (Nakamura et al., 1988) with modulation of monoamine turnover (the rate at which the brain produces and breaks down serotonin, dopamine, and noradrenaline). The evidence basis is one clinical pilot study in a mixed group of migraine, vasomotor headache (headache driven by widening and narrowing of blood vessels), chronic tinnitus, and psychogenic pain patients, using a loading schedule of daily injections followed by tapered dosing. The study had no control arm and compared each patient against their own recorded history, a design highly vulnerable to regression to the mean (the tendency for unusually severe symptoms to drift back toward their average on their own) in fluctuating pain conditions.

Magnitude: Pain levels fell significantly in 6 of 7 patients given five consecutive daily intravenous injections followed by five further injections at 48 to 72 hour intervals (Larbig et al., 1984).

Extended Maximum Lifespan and Reduced Spontaneous Tumour Incidence in Rodents

Lifelong intermittent DSIP dosing extended the tail of the survival curve and sharply reduced spontaneous tumours in a cancer-prone mouse strain, without changing average lifespan. The proposed mechanism is reduced accumulation of chromosome damage combined with the antioxidant effects described above. The evidence basis is two studies from the same St. Petersburg group in the same mouse strain, using the Deltaran preparation supplied by the institute that synthesized it — a direct interest of the developers in the outcome, which is not disclosed as a limitation in either paper. No lifespan data exist in any other species, and the selective extension of maximum but not mean lifespan is an unusual pattern that warrants caution.

Magnitude: In female SHR mice dosed at approximately 100 µg/kg for five consecutive days each month from 3 months of age, mean lifespan was unchanged, lifespan of the last 10% of survivors rose 17.1% and maximum lifespan 24.1%, total spontaneous tumour incidence fell 2.6-fold, and chromosome aberrations in bone marrow fell 22.6%; a later study in the same strain at 5 µg/kg reported a 16% increase in last-decile lifespan (Voitenkov et al., 2009).

Reduced Oxidative Protein Damage and Protein Glycation During Aging

In aging rats, intermittent DSIP reduced the accumulation of oxidized proteins across multiple tissues and lowered non-enzymatic glycation of haemoglobin, the sugar-driven modification of proteins that accumulates with age and with poor glucose control. The proposed mechanism is upregulation of endogenous antioxidant enzymes rather than direct radical scavenging. The evidence basis is a series of rodent studies from one laboratory using consistent dosing; the effects were tissue-specific, being strongest in spleen and myocardium and weakest in skeletal muscle. No equivalent measurements have been made in humans.

Magnitude: Subcutaneous dosing at 100 µg/kg for five days per month from 2 to 24 months of age reduced protein carbonyl accumulation and haemoglobin glycation relative to untreated age-matched animals across spleen, myocardium, testis, liver, and skeletal muscle (Bondarenko et al., 2012).

Improved Glucose Handling and Wellbeing in Older Adults with Type 2 Diabetes

A short course of the Deltaran preparation in elderly diabetic patients was followed by improvements in memory, mood, emotional stability, anxiety, and sleep quality, alongside lower post-load glucose and reduced growth hormone. The proposed mechanism is a combination of improved sleep, reduced sympathetic drive, and the antioxidant effects seen in animals. The evidence basis is a single open-label pilot in 11 patients with no control group, multiple simultaneous endpoints, and no correction for multiple comparisons (a statistical adjustment that guards against chance findings when many outcomes are tested at once), conducted by investigators working with the preparation’s developers. It is hypothesis-generating only.

Magnitude: In 11 patients aged around 66 with a mean 12.5 years of diabetes, 20 daily doses were followed by significant improvement in recent memory, mood, emotional lability, and anxiety, reduced post-load glycaemia, and reduced basal and stimulated growth hormone (Odin et al., 2004).

Reduced Seizure Susceptibility in Animal Models

DSIP lowers the incidence, severity, and duration of chemically provoked seizures in rats, and it strengthens the effect of a conventional antiepileptic drug given at a dose that is not protective on its own. The proposed mechanism is the same blockade of glutamate-driven cortical excitation described in the mechanism section, together with a shift of the electroencephalogram toward delta and theta activity. The evidence basis is three rodent studies from a single Belgrade laboratory using one seizure model, with no human data of any kind and no replication by an independent group. Its relevance here is chiefly as corroboration that the peptide dampens cortical excitation, rather than as a therapeutic prospect in its own right.

Magnitude: In chemically provoked sound-triggered (audiogenic) seizures in adult Wistar rats, DSIP at 1.0 mg/kg significantly reduced seizure incidence, mean seizure grade, and convulsion duration (Stanojlović et al., 2005), and combined with a non-protective 50 mg/kg valproate dose it significantly prolonged latency to seizure for 6 hours without causing motor impairment (Hrncić et al., 2006).

Reduced Anxiety-Like Behaviour in Rodents

Lifelong intermittent DSIP dosing lowered anxiety-like behaviour and raised exploratory activity in mice, an effect reported alongside the lifespan and tumour findings in the same animals. The proposed mechanism is the same stress-adaptive modulation that dominates the Russian interpretation of the peptide, together with dampened cortical excitation, rather than a benzodiazepine-like action on the calming messenger system. The evidence basis is a single mouse study from the St. Petersburg group using two standard behavioural tests, with no human anxiety data of any kind and the same developer conflict that applies to the rest of that programme. Its practical weight is low: behavioural measures in mice translate poorly to subjective anxiety in people, and no independent laboratory has repeated the observation.

Magnitude: Female SHR mice on monthly 5-day courses of 5 µg/kg spent 73% more time in the open arms of the elevated plus maze and explored the arm extremities nine times more often than controls, with significantly higher vertical activity in the open-field test from 6 months of age onward (Voitenkov et al., 2009).

Speculative 🟨

Mitochondrial Efficiency and Stress Resilience

DSIP increases the efficiency with which mitochondria convert oxygen consumption into usable energy and protects that capacity under low-oxygen conditions. There are no controlled human studies of this effect; the basis is isolated rat brain mitochondria, rat brain homogenates, and whole-animal hypoxia experiments from a single laboratory, supported by rodent restraint-stress and cold-stress models showing preserved liver and tissue function. Whether any of this translates to a person taking a few hundred micrograms before bed is entirely unknown.

Neuroprotection After Ischaemic Injury

Intranasal DSIP improved motor recovery after experimentally induced stroke in rats, and a structural analogue reduced both cardiac and brain infarct size when given at the moment blood flow was restored. No controlled human data exist. The signal is not uniformly favourable: in a pilot arm, administering the peptides during the occlusion phase rather than at reperfusion resulted in 100% mortality, so timing appears to determine whether the effect is protective or harmful.

Circadian and Melatonin Rhythm Support ⚠️ Conflicted

DSIP-like immunoreactivity in plasma follows a daily rhythm, and the peptide modulates the pineal enzyme that gates melatonin synthesis. The proposal that supplemental DSIP can realign a disrupted body clock rests entirely on this mechanistic and rodent work; no human study has measured circadian phase, melatonin output, or shift-work adaptation after DSIP administration, and the direction of the pineal effect has been reported as both stimulatory and inhibitory depending on the model.

Benefit-Modifying Factors

Baseline sleep disturbance: The single most consistent modifier in the human record. Every trial reporting benefit studied people with severe, long-standing insomnia; the one study of healthy men found only minor changes in sleep architecture. Someone already sleeping 7 to 8 hours with normal continuity has little measurable headroom, and the expected signal is correspondingly small.
Genetic polymorphisms: No pharmacogenetic data exist for DSIP specifically, and because the peptide is cleared by peptidases rather than liver enzymes, the usual drug-metabolism variants are unlikely to matter. Variants plausibly relevant on mechanistic grounds are COMT (catechol-O-methyltransferase, the enzyme that clears dopamine and noradrenaline from the prefrontal cortex), where slow-clearing variants are associated with higher arousal and worse sleep continuity, and PER3 (period circadian regulator 3, a core clock gene), whose length variants influence slow-wave sleep pressure. Both are speculative modifiers here, not established ones.
Baseline biomarker levels: Elevated evening cortisol, elevated overnight heart rate, and suppressed heart rate variability define a hyperarousal phenotype in which any sleep intervention performs differently from the low-arousal phenotype. Baseline slow-wave sleep percentage is the most directly relevant marker: those already at the upper end of the normal 13 to 23% band have less room to gain.
Sex-based differences: No study has reported sex-stratified results for DSIP, and the one modern randomized human study enrolled women exclusively, so male data in that setting are absent. Slow-wave sleep declines earlier and faster in men than in women across adulthood, which implies larger potential headroom in middle-aged men, but this is an inference from sleep physiology rather than a DSIP finding.
Pre-existing health conditions: Untreated obstructive sleep apnoea, in which breathing repeatedly stops during sleep, fragments slow-wave sleep mechanically and will blunt or nullify any pharmacological attempt to increase it. Depression, chronic pain, and restless legs each independently degrade sleep continuity and were the conditions in which the largest reported responses occurred, suggesting the peptide’s effect may be partly on the comorbidity rather than on sleep directly.
Age-related considerations: Slow-wave sleep declines steeply from the third decade onward, and the geroprotective animal work used lifelong intermittent dosing beginning in early adulthood, not late-life rescue. Older adults at the upper end of the target range have the greatest deficit and therefore the greatest theoretical headroom, but also the least representation in the human trial record, where participants were described as middle-aged.

Potential Risks & Side Effects

High 🟥 🟥 🟥

Unverified Identity, Purity, and Sterility of Grey-Market Material

The most concrete documented hazard is not a pharmacological effect but the product itself. Regulators reviewing the peptide in 2026 concluded that “DSIP” is a common name covering different active molecules, with amino acid counts and molecular weights varying between vendors, and that neither the free base nor the acetate salt is adequately characterized, citing inconsistent naming across the three standard nomenclature systems and missing characterization data. Impurity data were described as incomplete, with immunogenicity concerns tied directly to that gap. Because compounders are not required to submit adverse event reports and most online material is labelled for research use only, there is no surveillance system that would detect a contaminated or misidentified batch. The practical consequence is that dose, identity, and sterility are all unverified at the point of use.

Magnitude: In the July 2026 advisory review, both emideltide free base and emideltide acetate were judged not well characterized; the committee voted 6 in favour to 7 against inclusion on the compounding list, with 1 abstention, citing low-quality efficacy evidence, poor characterization, existing approved alternatives, and uncertainty about the dosing regimen (Snow et al., 2026).

Medium 🟥 🟥

Headache

Headache is the adverse event most consistently reported across the clinical literature and the one most frequently described in current practice, typically appearing within hours of dosing and resolving without intervention. The proposed mechanism is vasomotor, consistent with the peptide’s documented effects on cerebral blood flow and monoamine turnover. The evidence basis is the largest published clinical series, where headache in a minority of patients was the only tolerability problem noted, together with consistent practitioner reports. It is generally described as dose-related, which makes it the practical signal for having exceeded an individual’s threshold.

Magnitude: Reported in a minority of the 107 inpatients treated intravenously in the largest published series, in which overall tolerance was otherwise described as good.

Paradoxical Cortical Arousal and Autonomic Activation ⚠️ Conflicted

The only modern randomized human study of DSIP found the opposite of what its name predicts: the peptide reduced delta rhythm, reduced burst suppression (the alternation between brief bursts of brain electrical activity and near-flat intervals that marks deep anaesthesia), and increased a processed depth-of-anaesthesia score, meaning it lightened rather than deepened the anaesthetized state, while raising heart rate and lowering heart rate variability. The proposed mechanism is reduced parasympathetic tone (the activity of the nervous system’s rest-and-recover branch, which slows the heart). The evidence basis is a randomized controlled study with a bilateral electrode montage, which is methodologically stronger than any of the 1980s sleep studies. This directly conflicts with the delta-promoting findings that founded the field; possible reconciliations are the anaesthetized rather than natural sleep state, and the U-shaped dose-response curve, since the paradoxical effect was clearest at the lowest dose.

Magnitude: Among 24 women enrolled, the 12 randomized to DSIP at 25, 50, or 100 nmol/kg intravenously — against 12 saline controls — showed a significant rise in heart rate and fall in heart rate variability; at 25 nmol/kg during isoflurane anaesthesia, delta rhythm and burst suppression fell while the bispectral index rose, and left-right EEG symmetry was significantly altered (Pomfrett et al., 2009).

Low 🟥

Nausea, Dizziness, and Gastrointestinal Upset

Transient nausea, light-headedness, and abdominal discomfort are reported in the hours after dosing, most often at higher doses or with rapid intravenous administration. The mechanism is not established; central monoamine effects and vagal modulation are both plausible given the peptide’s documented autonomic actions. The evidence basis is scattered mentions in the older clinical reports and consistent contemporary practitioner and user reports rather than any systematic tolerability assessment. Severity is described as mild and self-limiting, and subcutaneous dosing appears to produce less of it than the intravenous route used in the original trials.

Magnitude: Not quantified in available studies.

Injection-Site Reactions and Infection Risk

Redness, swelling, itching, and localized pain at the injection site follow from subcutaneous administration of a lyophilized (freeze-dried) powder reconstituted by the user, and carry a small but real risk of abscess or bloodstream infection when reconstitution or storage is not aseptic. The mechanism is a combination of local histamine release, vehicle irritation, and introduced contamination. The evidence basis is generic to self-administered injectable peptides rather than DSIP-specific, since no trial systematically recorded local reactions; the risk is amplified here because the material is frequently supplied as a non-sterile research chemical rather than a pharmacy-compounded sterile preparation.

Magnitude: Not quantified in available studies.

Thermoregulatory Shifts

DSIP alters body temperature rhythms in animals, modifying hypothermic circadian cycles and interacting with the pineal and pituitary systems that govern them. The mechanism involves central thermoregulatory pathways shared with melatonin. The evidence basis is rodent work only (Yehuda & Mostofsky, 1984); no human study has measured core temperature after DSIP. The practical relevance is that a downward shift in evening core temperature is part of normal sleep onset, so this may be mechanistically supportive rather than adverse, but an exaggerated or mistimed shift has not been excluded.

Magnitude: Not quantified in available studies.

Speculative 🟨

Immunogenicity and Antibody Formation

Peptides of this size can provoke antibody formation, particularly when impurities or aggregated material are present, which could produce allergic reactions or neutralize the peptide’s effect over time. This concern was raised explicitly during the 2026 regulatory review and was tied to incomplete impurity data rather than to any observed case. No controlled data exist; there are no published reports of anti-DSIP antibodies in treated humans, and the basis is mechanistic and regulatory inference only.

Tolerance, Dependence, and Rebound Insomnia

Because part of DSIP’s early rationale was naloxone-reversible action on opioid-linked pathways, and because it was used specifically to treat opioid and alcohol withdrawal, the question of whether chronic use produces tolerance or a withdrawal state of its own is a reasonable one. No controlled data address it. The counter-observation from the original clinical work is that sleep improvement persisted into untreated nights and, in one open series, for months after the injection course ended, which is the opposite of a rebound pattern; the basis remains mechanistic and anecdotal.

Neuroendocrine Suppression of the Stress-Hormone Axis ⚠️ Conflicted

DSIP was proposed as an inhibitor of corticotropin release, which would imply a risk of blunted cortisol response with sustained use. The rodent work supports the inhibitory effect; the one direct human test found no effect whatever on adrenocorticotropic hormone or cortisol under either hormonal or meal stimulation. No controlled data show suppression in humans, so the risk rests on animal findings that human testing has so far failed to confirm.

Unknown Effects in Pregnancy, Lactation, and Long-Term Use

DSIP-like material occurs naturally in human milk, but no reproductive or developmental toxicity study of exogenous DSIP has been published, and no human has been followed on continuous administration for longer than the few weeks covered by the original trials. There is no controlled evidence in either direction; the basis is the complete absence of data, which is itself the finding.

Risk-Modifying Factors

Genetic polymorphisms: No variant is known to modify DSIP risk, and peptidase-mediated clearance makes the usual pharmacogenetic panel largely irrelevant. The theoretically relevant ones are OPRM1 (the mu-opioid receptor gene, which codes the main opioid binding site), given the naloxone-reversible component of the peptide’s action, and HLA class II variants (immune-system genes that determine which foreign fragments are presented to the immune system), which govern susceptibility to antibody formation against injected peptides. Neither has been studied here.
Baseline biomarker levels: Pre-existing elevation of high-sensitivity C-reactive protein or eosinophils raises the prior probability of a hypersensitivity reaction to an impure preparation. A low baseline heart rate variability or an existing resting tachycardia (a persistently fast heart rate) makes the documented autonomic activation more consequential, since the observed direction was toward higher heart rate and lower variability.
Sex-based differences: The only modern randomized safety data come from a study that enrolled 24 women exclusively, so the autonomic and EEG findings are, strictly speaking, uncharacterized in men. Women also show a higher background rate of injectable-drug hypersensitivity reactions generally, which would apply here.
Pre-existing health conditions: Cardiac arrhythmia or ischaemic heart disease makes the documented rise in heart rate and fall in heart rate variability materially more relevant. Untreated obstructive sleep apnoea is a concern with any agent marketed for deeper sleep, since deepening sleep without securing the airway can lengthen apnoeic events. A history of injection-related infection, immunosuppression, or bleeding disorder raises the local injection risk. Active substance use disorder deserves specific mention given the opioid-linked pharmacology.
Age-related considerations: Older adults clear injected peptides no more slowly in principle, but carry more polypharmacy, more cardiac disease, and thinner skin with poorer injection-site healing. At the older end of the target range the autonomic effect and the infection risk both matter more, while the trial population that generated the tolerability record was middle-aged, so the safety data do not extend cleanly upward.

Key Interactions & Contraindications

Sedative-hypnotics and benzodiazepines (zolpidem, zopiclone, eszopiclone, temazepam, diazepam): Caution. Additive sedation and next-morning impairment; DSIP was studied specifically in patients with a history of hypnotic dependence and the investigators flagged long-standing drug habits as a complicating factor. Mitigation described in practice: the two agents are not combined on the same night during the first two weeks, and where they are combined later the hypnotic dose is lowered first and administration separated by at least 2 hours.
Opioid analgesics (morphine, oxycodone, buprenorphine, methadone): Caution. The peptide’s original rationale was naloxone-reversible opioid-linked signalling, and it has been used to suppress opioid withdrawal, so additive central depression and masking of withdrawal cues are both plausible. Mitigation described in practice: the combination is not used unsupervised, and in opioid maintenance therapy it is handled as a prescriber-level decision.
General anaesthetics (isoflurane, propofol): Absolute contraindication in the perioperative window. The only modern randomized human study showed that DSIP lightened measured anaesthetic depth and altered left-right brain-wave symmetry during isoflurane anaesthesia, which introduces a risk of intraoperative awareness and confounds depth-of-anaesthesia monitoring. Mitigation described in practice: the peptide is discontinued at least 7 days before any procedure requiring general anaesthesia, and its use is disclosed to the anaesthetist.
Alcohol: Caution. Both act on the same slow-wave and opioid-linked pathways; alcohol independently suppresses the second half of the night. Mitigation described in practice: alcohol is omitted on dosing nights, both to prevent additive central depression and to avoid confounding any assessment of whether the peptide is working.
Over-the-counter sedating antihistamines (diphenhydramine, doxylamine): Caution. Additive next-day sedation with no evidence of additive benefit; both are found in the same night-time products. Mitigation described in practice: only one of the two agents is used at a time.
Over-the-counter analgesics (ibuprofen, naproxen, paracetamol): No known interaction. Because DSIP is cleared by peptidases rather than by cytochrome P450 liver enzymes, the interactions that dominate small-molecule pharmacology do not apply, and no case reports exist.
Melatonin: Caution, and specifically additive. DSIP modulates the pineal enzyme that gates melatonin synthesis, so exogenous melatonin acts on the same output pathway; the practical consequence is excessive morning inertia rather than danger. Mitigation described in practice: where both are used, melatonin is started at 0.3 to 0.5 mg rather than the common 3 to 10 mg and separated from the peptide by at least 60 minutes.
Sedating supplements (glycine, magnesium glycinate, L-Theanine, apigenin, valerian, GABA — gamma-aminobutyric acid, the brain’s principal calming messenger — and 5-HTP, 5-hydroxytryptophan, a serotonin building block): Caution, additive. Each independently lowers arousal or shortens sleep latency, so stacking them with DSIP makes attribution impossible and increases the risk of morning sedation. Mitigation described in practice: all of them are held for the first two weeks so that any observed effect can be attributed, then reintroduced one at a time.
Serotonergic agents (SSRIs — selective serotonin reuptake inhibitors, a widely used antidepressant class — and 5-HTP): Monitor. DSIP stimulates serotonin release from pineal tissue in animal preparations, and the theoretical concern is additive serotonergic load; no human case of serotonin excess has been reported with DSIP. Mitigation described in practice: agitation, tremor, and sweating are tracked during the first week of combined use.
Other longevity peptides (epitalon, semax, selank, growth hormone secretagogues — compounds that prompt the body to release its own growth hormone — such as ipamorelin and CJC-1295): Caution. These are frequently stacked in practice, all share the same unregulated supply chain, and each adds an independent source of injection-site reaction and immunogenicity. Mitigation described in practice: no more than one new peptide is introduced per four-week block.
Populations who should avoid DSIP: Pregnancy and lactation at any exposure, since no reproductive toxicity data exist. Anyone under 18, for the same reason. Anyone scheduled for surgery under general anaesthesia within 7 days. Untreated obstructive sleep apnoea with an apnoea-hypopnoea index of 15 or more events per hour until the airway is treated. Active or recent myocardial infarction within 90 days, unstable angina (chest pain arising from the heart at rest or worsening unpredictably), or uncontrolled arrhythmia (an irregular heart rhythm), given the documented rise in heart rate and fall in heart rate variability. Competitive athletes under anti-doping jurisdiction, since a substance not approved for human therapeutic use by any regulatory authority falls into the non-approved-substances category that is prohibited at all times with no therapeutic exemption available. Anyone with a history of anaphylaxis (a severe, whole-body allergic reaction) to an injected peptide or biologic.

Risk Mitigation Strategies

Licensed compounding pharmacy with a batch certificate of analysis: Mitigates the highest-graded risk, unverified identity and purity. The certificate sought shows purity by high-performance liquid chromatography of at least 98%, identity confirmed by mass spectrometry against the expected molecular weight of 849 daltons, and an endotoxin result below 0.25 endotoxin units per millilitre. Vials labelled “research use only” or “not for human consumption” fall outside this standard.
Low starting dose with slow titration: Mitigates headache, nausea, and the paradoxical arousal seen at the lowest studied intravenous dose. Protocols typically begin at 100 µg subcutaneously, hold that dose for 5 to 7 nights, and increase in 50 to 100 µg steps no more often than weekly, with escalation stopping at the first appearance of morning headache since that is the recognized dose-exceeded signal.
Single-variable trial window: Mitigates the risk of attributing effects incorrectly and of stacking additive sedatives. Melatonin, glycine, magnesium, valerian, and all sedating antihistamines are held for the first 14 nights, and nothing else about the sleep environment or schedule is altered during that window.
Strict aseptic reconstitution and storage: Mitigates injection-site reaction, abscess, and bloodstream infection. The standard practice is reconstitution with bacteriostatic water containing 0.9% benzyl alcohol rather than sterile water, swabbing of the stopper and the injection site with 70% isopropyl alcohol, a fresh insulin syringe for every dose, refrigeration at 2 to 8 °C, and disposal of the vial 28 days after reconstitution regardless of remaining volume.
Seven-day washout before general anaesthesia, with disclosure: Mitigates the documented risk of lightened anaesthetic depth and distorted depth-of-anaesthesia monitoring, which carries a risk of intraoperative awareness.
Airway screening before the first dose: Mitigates the risk of deepening sleep in the presence of untreated obstructive sleep apnoea, which can lengthen apnoeic events. Screening consists of a validated apnoea questionnaire, followed by a home sleep test before the first dose where the score is positive or a partner reports witnessed pauses.
Cardiovascular tolerance check over the first two weeks: Mitigates the risk from the documented rise in heart rate and fall in heart rate variability. Overnight resting heart rate and heart rate variability are recorded for 7 nights before starting and continuously afterwards; a sustained rise in resting heart rate of more than 5 beats per minute or a fall in heart rate variability of more than 15% from the personal baseline is treated as a stopping signal.
Cap on continuous exposure with reassessment: Mitigates the entirely unknown long-term risk profile, since no human has been followed beyond a few weeks of dosing. Continuous runs are capped at 8 weeks and followed by a minimum 4-week break, with objective sleep measurement during the break establishing whether the effect persists or reverses.

Therapeutic Protocol

Standard practitioner protocol: The most commonly described regimen in peptide-oriented practice is 100 to 300 µg subcutaneously, 30 to 60 minutes before intended sleep onset, given for 5 consecutive nights followed by 2 nights off, or continuously for 4 to 8 weeks followed by a break. This is a practice convention rather than a trial-derived schedule and it differs substantially from the published human trials.
Published trial protocol: Every controlled human sleep study used 25 nmol/kg intravenously — approximately 1.5 mg for a 70 kg adult, five to fifteen times the subcutaneous doses used in practice — administered in the afternoon or evening before the target night, for 3 to 7 consecutive nights. The clinical pilot in chronic pain used five consecutive daily intravenous injections followed by five further injections at 48 to 72 hour intervals. The discrepancy between the trial dose and the practice dose is one of the specific uncertainties regulators identified.
Competing approaches without a default: Three approaches coexist and none has been shown superior. The Basel clinical model treated DSIP as a short intensive course intended to reset disturbed sleep, with the effect expected to persist after the course ended. The Russian geroprotection model, developed around the Deltaran preparation at the Shemyakin-Ovchinnikov Institute, uses low-dose intermittent pulses — 5 consecutive days once per month, indefinitely — and targets stress resilience and oxidative damage rather than sleep. The contemporary longevity-practice model uses nightly low-dose subcutaneous administration as an ongoing sleep aid. The first is the only one with controlled human data; the second is the only one with lifespan data, in mice; the third has neither.
Named originators: The intensive intravenous course originates with Schneider-Helmert, Graf, and Schoenenberger at the University of Basel. The monthly-pulse geroprotection schedule originates with Mikhaleva and Ivanov at the Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry and Anisimov’s group at the Petrov Institute of Oncology; both institutions developed and supplied the preparation used in their own studies, so the schedule and the data supporting it come from the same interested source.
Best time of day: Evening. The trial protocols dosed in the afternoon before the target night, and current practice doses 30 to 60 minutes before bed. Morning dosing has not been studied and is mechanistically counterproductive given the peptide’s association with delta activity and its interaction with the melatonin pathway.
Half-life and its practical consequence: The plasma half-life is on the order of minutes, with proteolytic cleavage proceeding with a half-time of roughly 15 minutes in tissue preparations. This means the peptide is gone from circulation long before morning, so any overnight effect must be a triggered downstream response rather than sustained exposure — and equally, that a dose taken too early in the evening may have been fully cleared before sleep onset. Timing precision matters more here than with long-acting hypnotics.
Single versus split dosing: Single dosing. No study has evaluated split dosing, the U-shaped dose-response curve means a second dose is not reliably additive, and the short half-life offers no rationale for maintaining a level overnight. Splitting also multiplies injection-site exposure for no demonstrated gain.
Route selection: Subcutaneous injection into abdominal or thigh subcutaneous tissue is the dominant practice route. Intranasal administration has controlled human data behind it, in the study showing increased P300 response, and avoids injection-site risk entirely, but bioavailability by that route has never been quantified for DSIP, so intranasal dose equivalence is unknown.
Genetic polymorphisms influencing protocol: No pharmacogenetic guidance exists, and peptidase clearance makes the standard panel — CYP2C19, CYP2D6, and related drug-metabolizing enzyme variants — irrelevant to dose selection. COMT (catechol-O-methyltransferase, which clears dopamine and noradrenaline from the prefrontal cortex) slow-clearing genotypes are associated with higher evening arousal and may argue for the lower end of the dose range and earlier administration; APOE4 (a variant of the apolipoprotein E gene that affects fat transport and is the main common genetic risk factor for late-onset Alzheimer’s disease) carriers have documented slow-wave sleep deficits and a plausible interest in this endpoint, but no DSIP data exist in either group.
Sex-based differences in dosing: No study has reported sex-stratified dosing or response, and the trial doses were weight-normalized at 25 nmol/kg rather than sex-adjusted. The practice convention of a fixed 100 to 300 µg dose ignores body weight entirely, which implies a substantially higher exposure per kilogram in smaller individuals; weight-normalizing is the more defensible approach on the available pharmacology.
Age-related considerations: Older adults have the largest slow-wave sleep deficit and therefore the largest theoretical headroom, but no participant group in the human record was described as elderly except the 11-patient diabetes pilot. At the older end of the target range, practice conventions favour a 100 µg starting dose, a hold at each step extended from one week to two, and heavier weighting of cardiovascular monitoring.
Baseline biomarker influence on response: Objective baseline slow-wave sleep percentage is the single most informative pre-dose measurement, since it defines whether there is anything to improve. Evening cortisol and overnight heart rate variability distinguish the hyperarousal phenotype, in which sleep-onset latency is the most likely responsive endpoint, from the low-arousal phenotype, in which it is not.
Pre-existing conditions influencing response: Untreated obstructive sleep apnoea, restless legs, chronic pain, and depression each fragment sleep by a mechanism DSIP does not address, and will cap the achievable response. Conversely, the largest reported responses came from populations with exactly these comorbidities, so the peptide may be acting on the comorbid symptom rather than on sleep architecture — an ambiguity the existing trials cannot resolve.

Discontinuation & Cycling

Lifelong or short-term: The published human protocols are explicitly short-term — 3 to 7 nights, or a 10-injection course — and were designed on the premise that a disturbed sleep pattern could be reset rather than continuously suppressed. The only long-term dosing evidence of any kind is the monthly-pulse rodent lifespan work, which ran for the animals’ entire lives but at 5 days per month, not daily. Continuous nightly use for months or years, which is the dominant contemporary practice, has no supporting data in either direction.
Withdrawal effects: None have been documented. The original studies reported the opposite of a withdrawal pattern: sleep improvement was maintained through the first untreated placebo night after a seven-night course, and one open series reported normalized sleep persisting for 3 to 7 months after a 10-injection course ended. Whether this holds after months of nightly use is unknown, and the opioid-linked pharmacology means a dependence question cannot be dismissed on mechanism alone.
Tapering: No taper protocol has been studied and none appears necessary on the available evidence, given the absence of documented rebound and the short half-life. If a taper is used after prolonged nightly dosing, the conservative approach is to move to alternate nights for one week and then to twice weekly for one week, chiefly so that any rebound becomes visible gradually rather than abruptly.
Cycling for maintained efficacy: No tolerance has been demonstrated, so cycling is not established as necessary for efficacy. Two cycling patterns are in use: 5 nights on with 2 off, adopted from the trial protocols, and 8 weeks on with 4 weeks off. The stronger argument for cycling here is not tolerance but exposure limitation — capping cumulative exposure to a compound with no long-term human safety data, and creating measurement windows in which the untreated baseline can be re-established.
Assessment during breaks: The break itself is the most informative part of the protocol. Objective sleep measurement during a 4-week off-period reveals whether the reset effect described in the original trials is occurring or whether the peptide is functioning as a nightly dependency, which is the single most useful piece of individual data obtainable.

Sourcing and Quality

Supply channels and their differences: Three exist. Licensed compounding pharmacies operating under sterile-compounding standards produce material with documented sterility and potency but, in the United States, currently lack a clear legal pathway for this substance following the July 2026 advisory vote. Overseas pharmacies operate under varying and often unverifiable standards. Research-chemical vendors, which supply the majority of retail volume, sell material explicitly labelled not for human use, with no sterility assurance and no regulatory oversight of any kind.
What the characterization problem actually means: Regulators found that the same name is used for materials differing in amino acid count and molecular weight, and that naming is inconsistent across the assigned generic name, the international non-proprietary name, and the systematic chemical name. This is not a theoretical concern about trace impurities; it means two vials labelled DSIP may contain different molecules. The nonapeptide has a molecular weight of 849 daltons and the sequence Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu, and a certificate that does not confirm both leaves the material unverified.
Third-party testing requirements: Adequate documentation is a batch-specific certificate of analysis from a laboratory independent of the seller, showing purity of at least 98% by high-performance liquid chromatography, identity by mass spectrometry matching 849 daltons, water content by Karl Fischer titration below 8%, and bacterial endotoxin below 0.25 endotoxin units per millilitre by the amoebocyte lysate assay. Seller-generated certificates without an independent laboratory name and batch number are not third-party testing.
Formulation and physical form: DSIP is supplied as a white lyophilized powder, typically 2, 5, or 10 mg per vial, under vacuum. The free base has limited water solubility, a point regulators raised specifically because it implies that particle size distribution may need to be controlled; the acetate salt dissolves more readily and is the more common commercial form. A vial that does not hold vacuum on first puncture, or whose contents appear as a clumped or discoloured cake rather than a uniform white plug, is a compromised unit.
Reputable channels: Where legally available, a pharmacy compounding under United States Pharmacopeia sterile-compounding standards or an equivalent national standard is the only channel that provides sterility assurance for an injectable. Within that channel, accreditation is the available proxy for quality: pharmacies accredited by the Pharmacy Compounding Accreditation Board of the Accreditation Commission for Health Care, or registered as 503B outsourcing facilities, operate under audited sterility and potency controls that unaccredited compounders do not. No brand of research-chemical DSIP has independent verification of consistent quality; independent analytical laboratories that publish assays of retail peptide batches — Janoshik Analytical in Slovakia and Colmaric Analyticals in the United States are the two most widely used — are the only external check currently available to a buyer, and their published results for this compound class show frequent deviations from labelled content.
Storage and stability: Lyophilized powder is stable at 2 to 8 °C for the labelled shelf life and is light-sensitive; long-term storage below −20 °C is preferable for vials not in immediate use. Once reconstituted, the peptide degrades; refrigerated storage and disposal within 28 days is the convention. Because the peptide is cleaved rapidly by peptidases, any contamination that introduces proteolytic activity will silently reduce potency without visible change.

Practical Considerations

Time to effect: Faster than most sleep interventions. The original trials reported substantial improvement in night sleep from the first dose, with further gains over repeated nights, and practitioners describe a first-night response as typical. Where a subjective effect is going to appear, it appears within 1 to 3 nights; a full assessment of sleep architecture change requires 2 to 4 weeks of objective measurement.
Common pitfalls: Dosing too early in the evening, so that a peptide with a minutes-long half-life has been cleared before sleep onset. Escalating past the headache threshold on the assumption that more is better, when the dose-response curve is U-shaped and the only modern randomized study found paradoxical arousal at the lowest intravenous dose. Starting several sedating agents simultaneously, which makes attribution impossible. Relying on a consumer wearable’s slow-wave sleep estimate, which is an algorithmic approximation rather than a measurement, to judge whether the peptide is working. And treating research-chemical material as pharmaceutically equivalent to compounded material.
Regulatory status: DSIP is not approved as a medicine in any jurisdiction. In the United States it was placed in the compounding category reserved for substances presenting significant safety risks in 2023, removed from that category in April 2026, and considered by the Pharmacy Compounding Advisory Committee in July 2026, which declined to recommend it for the legal compounding list by 6 votes to 7 with 1 abstention; the agency has stated that the eventual proposed rule, not the committee vote, will determine the outcome. Most retail material is sold under a research-use-only exemption that does not contemplate human administration. For competitive athletes, a substance with no regulatory approval for human therapeutic use anywhere falls into the non-approved-substances category of the World Anti-Doping Agency prohibited list, which applies at all times and offers no therapeutic use exemption.
Cost and accessibility: Inexpensive relative to other longevity peptides. Research-grade material typically runs a low double-digit dollar amount per 5 mg vial, which at 200 µg per night is on the order of one to two months of use; pharmacy-compounded material where available costs several times that. Neither is covered by any insurer or national health system, and there is no institutional payer with an incentive to fund it, which also means no payer-funded comparative research is likely. Accessibility is limited less by price than by legal status and by the difficulty of verifying what has been purchased.

Interaction with Foundational Habits

Sleep: Direct and central — this is the intervention’s primary claimed target. The proposed direction is toward greater slow-wave and spindle activity with shorter sleep-onset latency, mediated by dampened cortical excitation rather than sedation. The evidence is split, and one randomized study in anaesthetized patients found the opposite direction. Practically, DSIP cannot substitute for sleep hygiene: consistent wake time, morning light exposure, and a dark cool bedroom set the ceiling on what any pharmacological agent can add, and every trial that reported benefit did so in a controlled sleep-laboratory environment. Dosing 30 to 60 minutes before a consistent lights-out time, rather than before a variable one, is the single most important practical consideration given the short half-life.
Nutrition: Indirect, with no known nutrient depletion. The peptide is cleaved into its constituent amino acids and consumes no cofactor. Two practical points follow from mechanism: a large meal within 2 hours of dosing raises core temperature and delays sleep onset, working against the intended effect, and evening alcohol suppresses slow-wave sleep in the second half of the night by a mechanism DSIP does not counteract. There is no evidence for or against taking it with food; injection makes gastrointestinal absorption irrelevant. Adequate protein intake matters generally for peptide-based interventions only in the trivial sense that it is a substrate, not as a modifier of this compound.
Exercise: Indirect and potentially potentiating in one direction, blunting in the other. Slow-wave sleep is when the bulk of overnight growth hormone release occurs, so anything that genuinely increases it plausibly supports recovery from training; this is the mechanistic basis for the peptide’s inclusion in recovery protocols, though no study has measured training adaptation with DSIP. In the opposite direction, vigorous exercise within 3 hours of bedtime raises core temperature and sympathetic tone and will blunt the sleep-onset effect. There is no evidence that DSIP blunts hypertrophy or interferes with training adaptation.
Stress management: Direct in animals, unconfirmed in humans, and this is the divergence that matters most. The Russian research programme characterizes DSIP primarily as a stress-adaptive modulator, with rodent data showing preserved liver function under restraint stress, restored antioxidant enzyme balance under cold stress, and reduced corticosterone response to the stress-hormone trigger. The one direct human test found no effect on the stress-hormone axis at all. Practically, the stress-buffering claim remains unverified in humans, and conventional stress management — regular practice, restricted evening cognitive load — remains the load-bearing element rather than the peptide.

Monitoring Protocol & Defining Success

Baseline testing is completed before the first dose and establishes three things: that no condition is present which makes the intervention unsafe, that there is a measurable sleep deficit to improve, and that a personal reference point exists for each marker that might change. A baseline sleep measurement over at least 7 consecutive nights carries as much weight as the blood work, since the peptide’s central claim is about sleep architecture and a single night is not interpretable.

Ongoing monitoring follows a front-loaded cadence: the autonomic and sleep measures run continuously from day 1 and are formally reviewed at 2 weeks and 8 weeks, the full blood panel is repeated at 8 to 12 weeks after starting, and thereafter every 6 to 12 months for as long as use continues.

Biomarker	Optimal Functional Range	Why Measure It?	Context/Notes
Slow-wave sleep percentage	13–23% of total sleep time	The peptide’s primary claimed endpoint	Measured with a home electroencephalography headband or a sleep-laboratory study; consumer wearable estimates are algorithmic approximations, not measurements. Averaged over 7 nights before and after
Sleep-onset latency	10–20 minutes	The endpoint that improved most consistently in the controlled trials	Recorded at a fixed lights-out time; latency below 5 minutes indicates sleep deprivation rather than a good result
Overnight heart rate variability	Within 10% of personal 7-night baseline	The documented autonomic effect was toward lower variability	HRV is heart rate variability, the beat-to-beat variation that reflects parasympathetic tone. Compared as 7-night rolling averages rather than single nights; a sustained fall over 15% is a stopping signal
Resting overnight heart rate	Within 5 bpm of personal baseline	Heart rate rose significantly in the one modern randomized study	Measured continuously by wearable during sleep; a sustained rise over 5 beats per minute is a stopping signal
Morning cortisol	10–15 µg/dL at 08:00	The stress-hormone axis is the mechanism most disputed between animal and human data	Drawn 30–60 minutes after waking, fasting. Conventional reference range is 6–23 µg/dL, wide enough to hide a meaningful shift
HbA1c	4.8–5.3%	Animal work showed reduced protein glycation; this is the human equivalent measure	HbA1c is glycated haemoglobin, an average of blood sugar over roughly three months. Conventional threshold is below 5.7%, which is considerably looser
Fasting insulin	2–5 µIU/mL	Detects the insulin-sensitizing signal reported in the small diabetes pilot	Requires a 10–12 hour fast; best paired with fasting glucose to calculate insulin resistance. Conventional reference ranges extend to about 25 µIU/mL, far above the functional target
hs-CRP	<0.5 mg/L	Rising values would suggest an inflammatory or hypersensitivity response to injected material	hs-CRP is high-sensitivity C-reactive protein, a general marker of inflammation. Conventional low-risk cut-off is below 3.0 mg/L. Not informative within 2 weeks of any infection
ALT and AST	10–26 U/L	Rodent work centres on liver protection under stress; these detect the opposite outcome	ALT is alanine aminotransferase and AST is aspartate aminotransferase, enzymes released when liver cells are damaged. Conventional upper limits of 40–50 U/L are far above the functional range
Complete blood count with differential	Eosinophils <3%; all indices within range	Rising eosinophils are the earliest signal of an allergic response to an impure peptide preparation	A complete blood count measures red cells, white cells, and platelets. Best drawn at the same visit as hs-CRP
Creatinine with eGFR	eGFR >90 mL/min/1.73 m²	Establishes renal reserve before adding any unapproved injectable	eGFR is estimated glomerular filtration rate, a calculated measure of how well the kidneys filter blood. Conventional practice treats anything above 60 mL/min/1.73 m² as normal, well below the functional target. Heavy protein intake or creatine supplementation within 48 hours before the draw distorts the result

Qualitative markers are recorded daily for the first 2 weeks and weekly thereafter, ideally with a single numeric rating for each rather than free text, so that trends are visible:

Sleep quality on waking: a 1–10 rating recorded within 10 minutes of waking, before checking any device.
Morning sleep inertia: presence and duration of the residual sleepiness that follows waking, which is the practical counterweight to any gain in sleep depth.
Daytime alertness and cognitive clarity: rated mid-afternoon, when the circadian dip makes differences most visible; this was the endpoint that improved in the seven-night controlled study.
Dream recall and dream character: shifts here indicate altered REM sleep and are commonly reported, though not systematically studied.
Mood and emotional stability: improved in both the chronic pain pilot and the diabetes pilot, and worth tracking independently of sleep.
Headache: presence, timing, and severity, since it is the recognized signal that the dose has been exceeded.
Injection site appearance: redness, swelling, or induration (hardening of the tissue) at 24 hours after each dose.

Success at 8 weeks means a measured increase in slow-wave sleep percentage or a measured reduction in sleep-onset latency that exceeds the night-to-night variation in the personal baseline, accompanied by improvement in daytime alertness, with no sustained rise in resting heart rate, no fall in heart rate variability, and no headache at the maintained dose. Improvement in subjective rating alone, without any objective change, is not distinguishable from expectation effects — which is precisely the ambiguity the original trials failed to resolve.

Emerging Research

No registered clinical trials: A ClinicalTrials.gov search on 08/05/2026 for delta sleep-inducing peptide, DSIP, emideltide, and Deltaran returned no registered interventional or observational study of the peptide, either ongoing or completed, and no NCT identifier exists to link. This is itself the most important fact about the current research pipeline: fifty years after isolation, and despite active commercial distribution, no sponsor has registered a controlled trial. The most recent controlled human data of any kind remain the 1992 sleep study and the 2009 anaesthesia study.
Blood-brain-barrier-optimized fusion peptides: The most active current direction is engineering around the peptide’s chief pharmacological weakness, its minutes-long half-life. A fusion construct pairing DSIP with a barrier-crossing sequence, secreted from Pichia pastoris yeast, outperformed unmodified DSIP at correcting serotonin, glutamate, dopamine, and melatonin imbalance and at promoting sleep in a chemically induced insomnia mouse model (Mu et al., 2024). If this line succeeds, it would strengthen the mechanistic case while simultaneously implying that unmodified DSIP is the wrong molecule to be administering.
Structural analogues with cardioprotective and neuroprotective signals: The KND analogue reduced myocardial infarct area to 19.1 ± 7.3% against 42.1 ± 9.2% in saline controls, and brain infarct volume to 7.4 ± 3.5% against 12.2 ± 5.6%, when given at the moment of reperfusion (Tukhovskaya et al., 2021). The same paper reports a finding that cuts the other way: administering the peptides during the occlusion phase instead produced 100% mortality, which is a serious warning about timing-dependent harm that has not been followed up.
Detoxification analogues in oncology support: Sixteen single- and double-substitution analogues were screened for antioxidant and detoxifying activity; the ID-6 analogue exceeded DSIP’s antioxidant activity, approached that of ascorbic acid and beta-carotene, and reduced acute cisplatin mortality in animals to 17% against 50–67% in controls, while normalizing liver enzymes and nitrogen waste products (Mikhaleva et al., 2014). This is the most concrete near-term clinical application proposed for the DSIP family, and again it favours the analogues over the parent peptide.
Recognition in mainstream clinical review: A 2026 review of therapeutic peptides in orthopaedics places DSIP among recovery-oriented peptides targeting circadian and mitochondrial regulators, while stating plainly that preclinical promise across this entire class is not matched by clinical trials (Rahman et al., 2026). Two of the three authors practise in clinics that provide peptide therapies, which is not disclosed as a competing interest in the review itself.
Evidence that could weaken the case: The most consequential open question is Kovalzon’s report that synthetic analogues promote slow-wave sleep in rabbits and rats while DSIP itself does not (Kovalzon & Strekalova, 2006). A direct modern replication of that comparison, using current electroencephalographic methods, would either rehabilitate or retire the founding claim. The paradoxical arousal finding in anaesthetized patients (Pomfrett et al., 2009) and the null human endocrine result (Späth-Schwalbe et al., 1995) point the same way and have likewise never been repeated.
Evidence that could strengthen the case: An adequately powered sleep-laboratory trial with full overnight recording of brain waves, breathing, and movement in adults with objectively measured low slow-wave sleep, using the subcutaneous doses actually in use rather than the intravenous doses of the 1980s, would test the modern claim directly for the first time. A replication of the mouse lifespan work by a laboratory independent of the preparation’s developers would address the most serious limitation of the geroprotection evidence, which is that every positive lifespan study to date shares authors with the institute that supplied the compound (Popovich et al., 2003).
Regulatory rulemaking as a research driver: The United States rulemaking that follows the July 2026 advisory review will determine whether the peptide has any legal supply channel, and the agency has confirmed it will analyse the full record including material submitted after its June 2026 evaluation (Snow et al., 2026). A legal channel would create traceable material and adverse-event visibility, which is the precondition for any usable safety dataset; continued exclusion leaves the current unmonitored market in place. The advocacy on both sides has a financial dimension: the case for inclusion was advanced largely by compounding pharmacies and telehealth peptide suppliers whose revenue depends on access, while the opposition included a consumer advocacy organization and an evidence-based-medicine body that do not derive revenue from the outcome.

Conclusion

DSIP is a nine-amino-acid chain first isolated from sleeping rabbits fifty years ago and still without a confirmed gene, source tissue, or docking site in the body. That gap shapes everything that follows. The human evidence consists of a handful of small studies conducted decades ago, mostly in people with severe long-term insomnia. Two of those studies reported that sleep became more efficient and that daytime alertness improved; two others found changes too small to matter. Studies in withdrawal from alcohol and opiates and in long-standing pain reported striking relief, but none of them used a comparison group. Everything pointing toward slower aging — longer maximum lifespan, fewer tumours, less oxidation damage — comes from mice and rats, at doses and schedules no one has tested in people.

The safety picture is thin rather than alarming. Reported side effects are mild and short-lived, chiefly headache. The larger hazard is the supply: what is sold under this name varies between sellers in length and weight, purity information is incomplete, and no regulator has confirmed what a given vial contains.

Much of the supporting research came from the laboratories that created the peptide preparations, and the push for wider access has come largely from the pharmacies and clinics that would sell it. For someone weighing this against well-studied sleep options, the evidence remains preliminary and unresolved.

Top - Benefits - Risks - Protocol

DSIP for Health & Longevity

Motivation

Recommended Reading

Grokipedia

Examine

ConsumerLab

Systematic Reviews

Mechanism of Action

Historical Context & Evolution

Expected Benefits

High 🟩 🟩 🟩

Medium 🟩 🟩

Reduced Sleep-Onset Latency and Improved Sleep Efficiency in Disturbed Sleep ⚠️ Conflicted

Improved Next-Day Alertness and Psychomotor Performance

Low 🟩

Symptom Relief During Alcohol and Opiate Withdrawal

Reduction in Chronic Pain Intensity

Extended Maximum Lifespan and Reduced Spontaneous Tumour Incidence in Rodents

Reduced Oxidative Protein Damage and Protein Glycation During Aging

Improved Glucose Handling and Wellbeing in Older Adults with Type 2 Diabetes

Reduced Seizure Susceptibility in Animal Models

Reduced Anxiety-Like Behaviour in Rodents

Speculative 🟨

Mitochondrial Efficiency and Stress Resilience

Neuroprotection After Ischaemic Injury

Circadian and Melatonin Rhythm Support ⚠️ Conflicted

Benefit-Modifying Factors

Potential Risks & Side Effects

High 🟥 🟥 🟥

Unverified Identity, Purity, and Sterility of Grey-Market Material

Medium 🟥 🟥

Headache

Paradoxical Cortical Arousal and Autonomic Activation ⚠️ Conflicted

Low 🟥

Nausea, Dizziness, and Gastrointestinal Upset

Injection-Site Reactions and Infection Risk

Thermoregulatory Shifts

Speculative 🟨

Immunogenicity and Antibody Formation

Tolerance, Dependence, and Rebound Insomnia

Neuroendocrine Suppression of the Stress-Hormone Axis ⚠️ Conflicted

Unknown Effects in Pregnancy, Lactation, and Long-Term Use

Risk-Modifying Factors

Key Interactions & Contraindications

Risk Mitigation Strategies

Therapeutic Protocol

Discontinuation & Cycling

Sourcing and Quality

Practical Considerations

Interaction with Foundational Habits

Monitoring Protocol & Defining Success

Emerging Research

Conclusion